Just saw Arcutis announced some solid phase 2 results for their atopic dermatitis cream - ZORYVE 0.05%. They tested it on babies 3-24 months old and 58% hit that EASI-75 improvement marker by week 4. Pretty impressive for such a young population honestly. The safety profile looked clean too, nothing concerning showed up over the 4 weeks they tracked. Stock was down 1.4% when I checked but these biotech moves can be weird sometimes. What's interesting is they already got FDA approval for the 2-5 year age group last year, so this data is basically paving the way to go even younger with dermatitis treatment. They're planning to file an sNDA next quarter to expand the indication. Makes sense - if it works safely in infants, that's a pretty big market opportunity for a pediatric dermatitis solution. Curious to see if the market reacts better when the filing actually drops.